Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and pharmacodynamics of IBI3016 in patients with mild to moderate hypertension. Multiple doses of IBI3016 will be tested against placebo, administered as subcutaneous injection.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Signed informed consent.
2. Males or females aged 18 to 75 years.
3. Diagnosis of primary hypertension without anti-HTN medication or with one anti-HTN medication
4. Mean sitting SBP ≥140 mmHg and \< 170 mmHg measured by OBPM.
5. Participants able to understand and comply with study procedures.
You may not be if
1. Known history of secondary hypertension.
2. Orthostatic hypotension.
3. Laboratory parameter assessments outside of range at screening：
* Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) \> 2× Upper Limit of Normal (ULN)
